Cadrenal Therape Stock Price, News & Analysis

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has provided a corporate update alongside its Annual Report for FY 2022. The company focuses on developing tecarfarin, a novel therapy with orphan drug and Fast Track designations from the FDA, aimed at preventing systemic thromboembolism in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib). Key highlights include the FDA's Fast Track designation for tecarfarin, the formation of a Scientific Advisory Board, and the successful completion of an IPO raising $7 million. A Phase 3 clinical trial, ACTOR-AF, is planned with the potential to address a significant market opportunity worth up to $1 billion annually if approved.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical firm, is advancing tecarfarin, a new therapy aimed at preventing systemic thromboembolism in patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib). During March, recognized as National Kidney Month, the company highlights the urgent need for effective treatments for this underserved group, which includes over 150,000 ESRD patients also suffering from AFib. With total Medicare spending for ESRD patients hitting $51 billion in 2019, tecarfarin's potential to reduce risks of stroke and mortality is significant. Currently, a Phase 3 clinical trial is being planned as the FDA shows interest.

Cadrenal Therapeutics (Nasdaq: CVKD) has announced that its CEO, Quang Pham, will ring the Nasdaq Stock Market closing bell on February 8, 2023. This event commemorates the company's recent IPO and the Fast Track designation granted by the FDA for tecarfarin, a novel therapy aimed at preventing cardiac-origin blood clots in patients with end-stage renal disease and atrial fibrillation. Tecarfarin has undergone 11 clinical trials and demonstrated good tolerance among participants. The ceremony is set to be broadcast live at 3:45 p.m. ET.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company, announced that CEO Quang Pham will hold one-on-one meetings at the BIO CEO & Investor Conference in New York from February 6-8, 2023. The company is focused on tecarfarin, a novel cardiorenal therapy designated as orphan drug and Fast Track for preventing systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. Tecarfarin has undergone eleven clinical trials with over 1,000 participants and has been well-tolerated. Interested parties can schedule meetings via the BIO Partnering system or contact Cadrenal directly.

Cadrenal Therapeutics (Nasdaq: CVKD) announced the formation of a Scientific Advisory Board (SAB) on February 1, 2023, to support the development of tecarfarin, aimed at preventing blood clots in patients with end-stage renal disease and atrial fibrillation. The SAB includes leading experts such as Christopher Bull Granger and Elaine Hylek, who will provide strategic guidance for advancing Cadrenal's mission. Tecarfarin has received orphan drug and Fast Track designations and has been tested in eleven clinical trials, showing promising tolerance in patients. This board aims to enhance the company’s capabilities in addressing cardiorenal diseases.